Abstract:Background: Food allergy prevalence has continued to rise over the past decade. While studies have reported threshold doses for multiple foods, large-scale multi-food allergen studies are lacking. Our goal was to identify threshold dose distributions and predictors of severe reactions during blinded oral food challenges (OFCs) in multi-food allergic patients. Methods: A retrospective chart review was performed on all Stanford-initiated clinical protocols involving standardized screening OFCs to any of 11 food allergens at 7 sites. Interval-censoring survival analysis was used to calculate eliciting dose (ED) curves for each food. Changes in severity and ED were also analyzed among participants who had repeated challenges to the same food. Results: Of 428 participants, 410 (96%) had at least one positive challenge (1445 standardized OFCs with 1054 total positive challenges). Participants undergoing peanut challenges had the highest ED50 (29.9 mg), while those challenged with egg or pistachio had the lowest (7.07 or 1.7 mg, respectively). The most common adverse event was skin related (54%), followed by gastrointestinal (GI) events (33%). A history of asthma was associated with a significantly higher risk of a severe reaction (hazard ratio [HR]: 2.37, 95% confidence interval [CI]: 1.36, 4.13). Higher values of allergen-specific IgE (sIgE) and sIgE to total IgE ratio (sIgEr) were also associated with higher risk of a severe reaction (1.49 [1.19, 1.85] and 1.84 [1.30, 2.59], respectively). Participants undergoing cashew, peanut, pecan, sesame, and walnut challenges had more severe reactions as ED increased. In participants who underwent repeat challenges, the ED did not change (p = 0.66), but reactions were more severe (p = 0.02). Conclusions: Participants with a history of asthma, high sIgEr, and/or high values of sIgE were found to be at higher risk for severe reactions during food challenges. These findings may help to optimize food challenge dosing schemes in multi-food allergic, atopic patients, specifically at lower doses where the majority of reactions occur. Trials Registration Number: ClinicalTrials. gov number NCT03539692; https://clinicaltrials.gov/ct2/show/NCT03539692.

Is Component-Specific Antibody Testing Sufficient to Replace the Oral Food Challenge in the Diagnostics of Peanut-Sensitized Children? A Proof-of-Concept Study

Predicting reactivity threshold in children with anaphylaxis to peanut

Diagnosing peanut allergy with skin prick and specific IgE testing

Peanut Allergy in Children—Is Prevention Better than Cure?

Oral Food Challenge in Children with Tree Nut and Peanut Allergy: The Predictive Value of Diagnostic Tests

Can we predict severe reactions during peanut challenges in children?

Serologic Measurements for Peanut Allergy: Predicting Clinical Severity is Complex

The predictive value of skin prick testing for challenge-proven food allergy: a systematic review

Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy

Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years

Optimizing tools for evaluating challenge outcomes in children with cashew nut allergy

Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children

Successful introduction of peanut in sensitized infants with reported reactions at home

Oral food challenges in children with a diagnosis of food allergy

Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis

The Natural History of IgE-Mediated Food Allergy: Can Skin Prick Tests and Serum-Specific IgE Predict the Resolution of Food Allergy?

Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges

Joint transcriptomic and cytometric study of peanut allergic children reveals molecular and cellular cross-talk in reaction thresholds

Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Combinatorial advantage of Ses i 1-specific IgE and basophil activation for diagnosis of sesame food allergy

Peanut allergen characterization and allergenicity throughout development